NCT07585799 Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conduction
| NCT ID | NCT07585799 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Óscar Cano Pérez |
| Condition | Bradycardia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-07-29 |
| Primary Completion | 2028-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-07-29 with a primary completion date of 2028-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intraventricular conduction delay alone or in combination with AV conduction delay is associated with a dyssynchronous activation of the ventricles and may result in LV function impairment. Conduction system pacing can restore physiologic ventricular activation in the presence of intraventricular and atrioventricular conduction delays. Patients with intraventricular conduction delay alone or in combination with AV conduction delay who have a permanent pacemaker indication due to intermittent bradycardia and have predominantly intact AV conduction may benefit from continuous CSP.
Eligibility Criteria
Inclusion Criteria: * age \> 18 years * Any indication for cardiac pacing with an expected VP burden ≤ 10% after 1- month run-in period * Baseline wide QRS (≥150 ms) with normal PR or QRS ≥ 130 ms + PR≥230 ms * LVEF≥50% * Confirmed CSP criteria * Signed and dated informed consent Exclusion Criteria: * Pregnant woman * Permanent or long-lasting atrial fibrillation * Previous PM/ICD * Unstable angina, acute Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), Percutaneous Coronary Angioplasty (PCI), surgical valve repair or replacement within 90 days prior enrollment * Moderate-severe valvular heart disease (unrepaired) * Already included in another clinical study that could confound the results of the present study * Infiltrative disease or any other genetically or acquired primary myocardial disease * Life expectancy \< 2 years * LVEF \<50%
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07585799 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bradycardia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07585799 currently recruiting?
Yes, NCT07585799 is actively recruiting participants. Contact the research team at cano_osc@gva.es for enrollment information.
Where is the NCT07585799 trial being conducted?
This trial is being conducted at Granada, Spain, Zaragoza, Spain, Valencia, Spain.
Who is sponsoring the NCT07585799 clinical trial?
NCT07585799 is sponsored by Óscar Cano Pérez. The trial plans to enroll 120 participants.